Clinical Trial Update: A Study of Imvotamab in Severe Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 study of Imvotamab for severe systemic lupus erythematosus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Imvotamab (imvotamab)

Snippet

Sponsor: IGM Biosciences, Inc. | Conditions: Systemic Lupus Erythematosus, Lupus Erythematosus | Phase 1 | Status: TERMINATED